Quantum Pharma announces Lamda out-licensing agreements
Quantum Pharma Plc (AIM: QP.), the growing service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, is pleased to announce a succession of out-licensing deals across Europe from its recently acquired division, Lamda.
A generic plus dossier containing an undisclosed Active Pharmaceutical Ingredient ("API"), which Lamda co-developed, has been out-licensed to a French-based pharmaceutical company in over 40 territories from which Lamda is receiving licensing fees and rights to future royalty income.
Lamda has also out-licensed a generic dossier for an undisclosed API to a pharmaceutical company for a fixed license fee with a royalty over five years once the product is licensed in Germany.
The continued commercialisation of the latent value held within Lamda's 100 plus projects is encouraging, and Quantum believes that Lamda will continue to develop as described at the time of acquisition.
Andrew Scaife, CEO of Quantum Pharma, said: "At the time of acquisition we stated that part of the upside potential within Lamda was its ability to out-licence products, and these initial two European out-licensing deals demonstrate that. These out-licences see Quantum's stated business plan for Lamda developing as anticipated, and we expect to see further deals in the coming months. Since IPO, Quantum has significantly diversified both its product portfolio and its infrastructure, and with this has come a number of potential new income streams and an increased platform of strategic partners in Europe."
Posted by: Quantum Webmaster on 15th October 2015